+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Peptide Drug Conjugates Market Size, Share & Trends Analysis Report by Product (Illuccix, Pluvicto, CBX-12, Pipeline Products), Type (Diagnostic, Therapeutic), and Region with Growth Forecasts, 2025-2030- Product Image
Peptide Drug Conjugates Market Size, Share & Trends Analysis Report by Product (Illuccix, Pluvicto, CBX-12, Pipeline Products), Type (Diagnostic, Therapeutic), and Region with Growth Forecasts, 2025-2030- Product Image
New

Peptide Drug Conjugates Market Size, Share & Trends Analysis Report by Product (Illuccix, Pluvicto, CBX-12, Pipeline Products), Type (Diagnostic, Therapeutic), and Region with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 100 Pages
  • February 2025
  • Region: Global
  • Grand View Research
  • ID: 5702099
Description Jump to:
The Peptide Drug Conjugates Market was valued at USD 3.73 billion in 2024, and is projected to reach USD 12.84 billion by 2030, rising at a CAGR of 19.21%. The growth of market is attributed to the global upsurge in cancer cases and related mortality, strong clinical trial pipeline with peptide drug conjugates (PDCs) and associated side effects of the existing products such as uncontrolled toxicity associated with small molecule chemotherapeutic agents.

According to WHO, cancer is the leading cause of disease related deaths, worldwide. In 2020, around 10.0 million deaths globally and more than 6.0 million deaths in the U.S. were recorded due to the cancer. Furthermore, as per cancer.gov, by 2040, the new cancer cases patients per year is estimated to reach to 29.0 million and the number of cancer-related deaths to 16.0 million. Therefore, rising demand for the novel treatment like PDCs to target uncontrolled cell growth is expected to fuel the peptide drug conjugates market growth.

Currently, Lutathera (Lu 177 dotatate) and Pepaxto (Melflufen) are the two FDA approved PDCs to treat uncontrolled cell growth. The marketplace has the FDA approved PDC as the Novartis’s Lutathera (lutetium Lu 177)indicated for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults. Later, in February 2021, Oncopeptides ABs announced the FDA’s accelerated approval for Pepaxto (Melphalan) indicated for the treatment in multiple myeloma. Presence of limited PDCs in space in offering remunerative opportunity for the growth.

Furthermore, presence of robust clinical trial pipeline and expected launch of new PDCs is anticipated to boost the market growth during the forecast period. These can attribute due to the PDC ANG1005 under phase 3 clinical studies for brain tumor, and PDCs BT5528 and BT1718 under phase 2 to clinical studies for lung cancer. CBX-12 is another phase 2 PDC candidate indicated for the small cell lung cancer treatment.

Key players are undertaking strategic initiatives such as collaborations, merger & acquisitions, agreements, along with financial investments, which is driving the market growth. For instance, in December 2021, Coherent Biopharma and WuXi STA announced the strategic partnership agreement to develop their current and future therapeutic drugs including peptide drug conjugates.

Peptide Drug Conjugates Market Report Highlights

  • The therapeutic segment dominated the industry in 2024 and is anticipated to witness the fastest growth.
  • The pluvicto segment dominated the industry with a revenue share of 42.52% in 2024 and is expected to exhibit the fastest CAGR over the forecast period.
  • North America peptide drug conjugates market held a leading position in 2024, accounting for 75.02% of the global share.

This report addresses:

  • Market intelligence to enable effective decision-making.
  • Market estimates and forecasts from 2018 to 2030.
  • Growth opportunities and trend analyses.
  • Segment and regional revenue forecasts for market assessment.
  • Competition strategy and market share analysis.
  • Product innovation listings for you to stay ahead of the curve.
  • COVID-19's impact and how to sustain in this fast-evolving market.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Peptide Drug Conjugates Market Variables, Trends, & Scope
3.1. Parent Market Outlook
3.2. Ancillary Market Outlook
3.3. Market Dynamics
3.3.1. Market drivers analysis
3.3.1.1. Rising prevalence of neurological disorders increasing disease prevalence
3.3.1.2. Robust clinical trial pipeline
3.3.1.3. Growing focus on targeted drug delivery
3.3.2. Market Restraints Analysis
3.3.2.1. Long R&D time and slow clinical development process
3.3.2.2. Stringent regulations associated with peptide drug conjugates (PDC’s)
3.4. Dopamine Agonist Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
3.5. Pipeline Analysis
3.5.1. Phase 1
3.5.2. Phase 2
3.5.3. Phase 3
Chapter 4. Peptide Drug Conjugates Market: By Product Estimates & Trend Analysis
4.1. Peptide Drug Conjugates Market: Product Segment Dashboard
4.2. Peptide Drug Conjugates Market: By Product Movement Analysis, 2024 & 2030 (USD Million)
4.3. Illuccix
4.3.1. Illuccix Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.4. Pluvicto
4.4.1. Pluvicto Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.5. Lutathera
4.5.1. Lutathera Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.6. OctreoScan
4.6.1. OctreoScan Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.7. Others
4.7.1. Others Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 5. Peptide Drug Conjugates Market: Type Estimates & Trend Analysis
5.1. Peptide Drug Conjugates Market: Type Segment Dashboard
5.2. Peptide Drug Conjugates Market: By Type Movement Analysis, 2024 & 2030 (USD Million)
5.3. Therapeutics
5.3.1. Therapeutics Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
5.4. Diagnostics
5.4.1. Diagnostics Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 6. Peptide Drug Conjugates Market: Regional Estimates & Trend Analysis
6.1. Peptide Drug Conjugates Market Share, by Region, 2024 & 2030, USD Million
6.2. North America
6.2.1. North America Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.2.2. U.S.
6.2.2.1. Key Country Dynamics
6.2.2.2. Target Disease Prevalence
6.2.2.3. Regulatory Framework
6.2.2.4. Reimbursement Framework
6.2.2.5. U.S. Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.2.3. Canada
6.2.3.1. Key Country Dynamics
6.2.3.2. Target Disease Prevalence
6.2.3.3. Regulatory Framework
6.2.3.4. Reimbursement Framework
6.2.3.5. Canada Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.2.4. Mexico
6.2.4.1. Key Country Dynamics
6.2.4.2. Target Disease Prevalence
6.2.4.3. Regulatory Framework
6.2.4.4. Reimbursement Framework
6.2.4.5. Mexico Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.3. Europe
6.3.1. Europe Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.3.2. UK
6.3.2.1. Key Country Dynamics
6.3.2.2. Target Disease Prevalence
6.3.2.3. Regulatory Framework
6.3.2.4. Reimbursement Framework
6.3.2.5. Uk Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.3.3. Germany
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Regulatory Framework
6.3.3.4. Reimbursement Framework
6.3.3.5. Germany Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.3.4. France
6.3.4.1. Key Country Dynamics
6.3.4.2. Target Disease Prevalence
6.3.4.3. Regulatory Framework
6.3.4.4. Reimbursement Framework
6.3.4.5. France Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.3.5. Italy
6.3.5.1. Key Country Dynamics
6.3.5.2. Target Disease Prevalence
6.3.5.3. Regulatory Framework
6.3.5.4. Reimbursement Framework
6.3.5.5. Italy Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.3.6. Spain
6.3.6.1. Key Country Dynamics
6.3.6.2. Target Disease Prevalence
6.3.6.3. Regulatory Framework
6.3.6.4. Reimbursement Framework
6.3.6.5. Spain Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.3.7. Denmark
6.3.7.1. Key Country Dynamics
6.3.7.2. Target Disease Prevalence
6.3.7.3. Regulatory Framework
6.3.7.4. Reimbursement Framework
6.3.7.5. Denmark Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.3.8. Sweden
6.3.8.1. Key Country Dynamics
6.3.8.2. Target Disease Prevalence
6.3.8.3. Regulatory Framework
6.3.8.4. Reimbursement Framework
6.3.8.5. Sweden Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.3.9. Norway
6.3.9.1. Key Country Dynamics
6.3.9.2. Target Disease Prevalence
6.3.9.3. Regulatory Framework
6.3.9.4. Reimbursement Framework
6.3.9.5. Norway Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4. Asia Pacific
6.4.1. Asia Pacific Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.2. Japan
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Regulatory Framework
6.4.2.4. Reimbursement Framework
6.4.2.5. Japan Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.3. China
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Regulatory Framework
6.4.3.4. Reimbursement Framework
6.4.3.5. China Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.4. India
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Regulatory Framework
6.4.4.4. Reimbursement Framework
6.4.4.5. India Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.5. Australia
6.4.5.1. Key Country Dynamics
6.4.5.2. Target Disease Prevalence
6.4.5.3. Regulatory Framework
6.4.5.4. Reimbursement Framework
6.4.5.5. Australia Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.6. South Korea
6.4.6.1. Key Country Dynamics
6.4.6.2. Target Disease Prevalence
6.4.6.3. Regulatory Framework
6.4.6.4. Reimbursement Framework
6.4.6.5. South Korea Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.7. Thailand
6.4.7.1. Key Country Dynamics
6.4.7.2. Target Disease Prevalence
6.4.7.3. Regulatory Framework
6.4.7.4. Reimbursement Framework
6.4.7.5. Thailand Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5. Latin America
6.5.1. Latin America Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.2. Brazil
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Prevalence
6.5.2.3. Regulatory Framework
6.5.2.4. Reimbursement Framework
6.5.2.5. Japan Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.3. Argentina
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Regulatory Framework
6.5.3.4. Reimbursement Framework
6.5.3.5. China Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6. Middle East and Africa
6.6.1. Middle East and Africa Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2. South Africa
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Prevalence
6.6.2.3. Regulatory Framework
6.6.2.4. Reimbursement Framework
6.6.2.5. South Africa Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.3. Saudi Arabia
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Regulatory Framework
6.6.3.4. Reimbursement Framework
6.6.3.5. Saudi Arabia Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.4. UAE
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Regulatory Framework
6.6.4.4. Reimbursement Framework
6.6.4.5. UAE Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.5. Kuwait
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Regulatory Framework
6.6.5.4. Reimbursement Framework
6.6.5.5. Kuwait Peptide Drug Conjugates Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis by Key Market Participants
7.2. Company Categorization
7.3. Participant Overview
7.4. Financial Performance
7.5. Product Bench Marking
7.6. Company Market Share Analysis, 2024
7.7. Company Profiles
7.7.1. Novartis AG
7.7.1.1. Participant’s Overview
7.7.1.2. Financial Performance
7.7.1.3. Product Benchmarking
7.7.1.4. Recent Developments/ Strategic Initiatives
7.7.2. AstraZeneca
7.7.2.1. Participant’s Overview
7.7.2.2. Financial Performance
7.7.2.3. Product Benchmarking
7.7.2.4. Recent Developments/ Strategic Initiatives
7.7.3. Oncopeptides AB
7.7.3.1. Participant’s Overview
7.7.3.2. Financial Performance
7.7.3.3. Product Benchmarking
7.7.3.4. Recent Developments/ Strategic Initiatives
7.7.4. Bicycle Therapeutics
7.7.4.1. Participant’s Overview
7.7.4.2. Financial Performance
7.7.4.3. Product Benchmarking
7.7.4.4. Recent Developments/ Strategic Initiatives
7.7.5. Cybrexa
7.7.5.1. Participant’s Overview
7.7.5.2. Financial Performance
7.7.5.3. Product Benchmarking
7.7.5.4. Recent Developments/ Strategic Initiatives
7.7.6. Angiochem Inc.
7.7.6.1. Participant’s Overview
7.7.6.2. Financial Performance
7.7.6.3. Product Benchmarking
7.7.6.4. Recent Developments/ Strategic Initiatives
7.7.7. Soricimed Biopharma
7.7.7.1. Participant’s Overview
7.7.7.2. Financial Performance
7.7.7.3. Product Benchmarking
7.7.7.4. Recent Developments/ Strategic Initiatives
7.7.8. Theratechnologies Inc.
7.7.8.1. Participant’s Overview
7.7.8.2. Financial Performance
7.7.8.3. Product Benchmarking
7.7.8.4. Recent Developments/ Strategic Initiatives
Chapter 8. Conclusion
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 List of Parameters
Table 4 List of Distributors
Table 5 Global Peptide Drug Conjugates Market, by Region, 2018-2030 (USD Million)
Table 6 Global Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 7 Global Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 8 North America Peptide Drug Conjugates Market, by Country, 2018-2030 (USD Million)
Table 9 North America Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 10 North America Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 11 U.S. Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 12 U.S. Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 13 Canada Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 14 Canada Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 15 Mexico Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 16 Mexico Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 17 Europe Peptide Drug Conjugates Market, by Country, 2018-2030 (USD Million)
Table 18 Europe Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 19 Europe Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 20 Germany Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 21 Germany Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 22 UK Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 23 UK Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 24 France Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 25 France Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 26 Italy Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 27 Italy Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 28 Spain Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 29 Spain Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 30 Denmark Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 31 Denmark Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 32 Sweden Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 33 Sweden Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 34 Norway Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 35 Norway Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 36 Asia Pacific Peptide Drug Conjugates Market, by Country, 2018-2030 (USD Million)
Table 37 Asia Pacific Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 38 Asia Pacific Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 39 Japan Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 40 Japan Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 41 China Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 42 China Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 43 India Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 44 India Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 45 South Korea Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 46 South Korea Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 47 Australia Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 48 Australia Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 49 Thailand Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 50 Thailand Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 51 Latin America Peptide Drug Conjugates Market, by Country, 2018-2030 (USD Million)
Table 52 Latin America Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 53 Latin America Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 54 Brazil Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 55 Brazil Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 56 Argentina Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 57 Argentina Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 58 Middle East & Africa Peptide Drug Conjugates Market, by Country, 2018-2030 (USD Million)
Table 59 Middle East & Africa Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 60 Middle East & Africa Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 61 Saudi Arabia Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 62 Saudi Arabia Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 63 South Africa Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 64 South Africa Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 65 UAE Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 66 UAE Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
Table 67 Kuwait Peptide Drug Conjugates Market, by Product, 2018-2030 (USD Million)
Table 68 Kuwait Peptide Drug Conjugates Market, by Type, 2018-2030 (USD Million)
List of Figures
Figure 1 Peptide drug conjugates market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Value chain based sizing & forecasting
Figure 6 QFD modelling for market share assessment
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Product and type segment snapshot
Figure 10 Competitive landscape snapshot
Figure 11 Peptide therapeutics market value, 2024 (USD billion)
Figure 12 Market dynamics
Figure 13 Global number of new cases caused by top 11 cancer types in 2023 (in thousands)
Figure 14 Porter's five forces analysis
Figure 15 PESTLE analysis
Figure 16 Peptide Drug Conjugates market: Product outlook and key takeaways
Figure 17 Peptide drug conjugates market: Product movement analysis
Figure 18 Lutathera market estimates and forecast, 2018-2030 (USD Million)
Figure 19 OctreoScan market estimates and forecast, 2018-2030 (USD Million)
Figure 20 Illuccix market estimates and forecast, 2018-2030 (USD Million)
Figure 21 Pluvicto market estimates and forecast, 2018-2030 (USD Million)
Figure 22 Others market estimates and forecasts, 2018-2030 (USD Million)
Figure 23 Peptide drug conjugates market: Type outlook and key takeaways
Figure 24 Peptide drug conjugates market: Type movement analysis
Figure 25 Therapeutic market estimates and forecast, 2018-2030 (USD Million)
Figure 26 Diagnostic market estimates and forecast, 2018-2030 (USD Million)
Figure 27 Peptide drug conjugates market revenue, by region, 2024 & 2030 (USD Million)
Figure 28 Regional marketplace: Key takeaways
Figure 29 North America peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 30 Key country dynamics
Figure 31 U.S. peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 32 Key country dynamics
Figure 33 Canada peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 34 Key country dynamics
Figure 35 Mexico peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 36 Europe peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 37 Key country dynamics
Figure 38 UK peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 39 Key country dynamics
Figure 40 Germany peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 41 Key country dynamics
Figure 42 France peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 43 Key country dynamics
Figure 44 Italy peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 45 Key country dynamics
Figure 46 Spain peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 47 Key country dynamics
Figure 48 Denmark peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 49 Key country dynamics
Figure 50 Sweden peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 51 Key country dynamics
Figure 52 Norway peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 53 Rest of Europe peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 54 Asia Pacific peptide drug conjugates market estimates and forecast, 2018-2030 (USD Million)
Figure 55 Key country dynamics
Figure 56 Japan peptide drug conjugates market estimates and forecast, 2018-2030 (USD Million)
Figure 57 Key country dynamics
Figure 58 China peptide drug conjugates market estimates and forecast, 2018-2030 (USD Million)
Figure 59 Key country dynamics
Figure 60 India peptide drug conjugates market estimates and forecast, 2018-2030 (USD Million)
Figure 61 Key country dynamics
Figure 62 Australia peptide drug conjugates market estimates and forecast, 2018-2030 (USD Million)
Figure 63 Key country dynamics
Figure 64 Thailand peptide drug conjugates market estimates and forecast, 2018-2030 (USD Million)
Figure 65 Key country dynamics
Figure 66 South Korea peptide drug conjugates market estimates and forecast, 2018-2030 (USD Million)
Figure 67 Rest of Asia Pacific peptide drug conjugates market estimates and forecast, 2018-2030 (USD Million)
Figure 68 Latin America peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 69 Key country dynamics
Figure 70 Brazil peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 71 Key country dynamics
Figure 72 Argentina peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 73 Rest of Latin America peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 74 MEA peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 75 Key country dynamics
Figure 76 South Africa peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 77 Key country dynamics
Figure 78 Saudi Arabia peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 79 Key country dynamics
Figure 80 UAE peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 81 Key country dynamics
Figure 82 Kuwait peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 83 Rest of MEA peptide drug conjugates market estimates and forecasts, 2018-2030 (USD Million)
Figure 84 Company/competition categorization
Figure 85 Company market share analysis, 2024
Figure 86 Strategy mapping

Companies Mentioned

The major companies profiled in this Peptide Drug Conjugates market report include:
  • Novartis AG
  • AstraZeneca
  • Oncopeptides AB
  • Bicycle Therapeutics
  • Cybrexa
  • Angiochem Inc.
  • Soricimed Biopharma
  • Theratechnologies Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedFebruary 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 3.73 Billion
Forecasted Market Value ( USD ) by 2030 $ 12.84 Billion
Compound Annual Growth Rate19.2%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable, Non-cleavable), By Product, By Target, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable, Non-cleavable), By Product, By Target, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 125 Pages
  • Global
From
Constrained Peptide Drugs Market by Peptide Type, End-User - Global Forecast 2025-2030 - Product Image

Constrained Peptide Drugs Market by Peptide Type, End-User - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key Geographical Regions - Product Image

Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key Geographical Regions

  • Report
  • 716 Pages
  • Global
From
Antibody Drug Conjugates Contract Manufacturing Market by Linker, Condition, End Use - Global Forecast 2025-2030 - Product Image

Antibody Drug Conjugates Contract Manufacturing Market by Linker, Condition, End Use - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030 - Product Image

Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030

  • Report
  • 600 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.